<html><head><title>Results</title><meta charset="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/bulma/0.7.2/css/bulma.min.css"/><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bulma-extensions@4.0.1/dist/css/bulma-extensions.min.css"/><script src="https://use.fontawesome.com/releases/v5.3.1/js/all.js"></script><script src="https://cdn.jsdelivr.net/npm/bulma-extensions@4.0.1/dist/js/bulma-extensions.min.js"></script><script src="https://cdn.jsdelivr.net/npm/bulma-extensions@4.0.1/bulma-accordion/dist/js/bulma-accordion.min.js"></script></head><body><br/><div class="container"><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 11558817</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/11558817.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>latanoprost with that</td></tr><tr><th>Comparison Arm</th><td>dorzolamide when</td></tr><tr><th>Patient Group</th><td>148 patients with inadequately controlled open-angle or pseudoexfoliation glaucoma</td></tr><tr><th>Outcome Measure</th><td>The intraocular pressure</td></tr><tr><th>Result of Intervention</th><td>32 %</td></tr><tr><th>Result of Comparison</th><td>20 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 22775229</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/22775229.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>latanoprost 0.005 % /timolol</td></tr><tr><th>Comparison Arm</th><td>fixed combination</td></tr><tr><th>Patient Group</th><td>The patients underwent a 6-week treatment</td></tr><tr><th>Outcome Measure</th><td>Intraocular Pressure</td></tr><tr><th>Result of Intervention</th><td>-35.0 %</td></tr><tr><th>Result of Comparison</th><td>8.8 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 19383599</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/19383599.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>combined trabeculectomy and cataract extraction</td></tr><tr><th>Comparison Arm</th><td>combined trabeculectomy and cataract extraction</td></tr><tr><th>Patient Group</th><td>99 Chinese Primary Angle-Closure Glaucoma patients 75 patients underwent</td></tr><tr><th>Outcome Measure</th><td>a &gt; 20 % reduction</td></tr><tr><th>Result of Intervention</th><td>56 %</td></tr><tr><th>Result of Comparison</th><td>54 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 17825417</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/17825417.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>a 1-site phacotrabeculectomy</td></tr><tr><th>Comparison Arm</th><td>1-site fornix-based and 2-site limbus-based phacotrabeculectomy</td></tr><tr><th>Patient Group</th><td>76 patients with cataract and glaucoma</td></tr><tr><th>Outcome Measure</th><td>Intraocular pressure and number</td></tr><tr><th>Result of Intervention</th><td>78.4 %</td></tr><tr><th>Result of Comparison</th><td>less than 18 mmHg</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 17601060</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/17601060.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>long-acting 1 % carteolol hydrochloride eye drops</td></tr><tr><th>Comparison Arm</th><td>1 % carteolol hydrochloride eye drops</td></tr><tr><th>Patient Group</th><td>Patients with primary open-angle glaucoma</td></tr><tr><th>Outcome Measure</th><td>Intraocular pressure</td></tr><tr><th>Result of Intervention</th><td>-4.1 +/- 0.2 , -4.4 +/- 0.3</td></tr><tr><th>Result of Comparison</th><td>2 , 4</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 21035866</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/21035866.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>laser peripheral iridotomy</td></tr><tr><th>Comparison Arm</th><td>conversion or medication</td></tr><tr><th>Patient Group</th><td>116 patients with Pigment Dispersion Syndrome</td></tr><tr><th>Outcome Measure</th><td>The proportion</td></tr><tr><th>Result of Intervention</th><td>105 ( 90 % )</td></tr><tr><th>Result of Comparison</th><td>35.9 months</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 8628543</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/8628543.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>latanoprost administered</td></tr><tr><th>Comparison Arm</th><td>0.5 % timolol</td></tr><tr><th>Patient Group</th><td>patients with open-angle glaucoma</td></tr><tr><th>Outcome Measure</th><td>Diurnal Intraocular Pressure</td></tr><tr><th>Result of Intervention</th><td>25.2 to</td></tr><tr><th>Result of Comparison</th><td>determined at</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 16899528</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/16899528.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>argon laser trabeculoplasty</td></tr><tr><th>Comparison Arm</th><td>the Argon Laser Trabeculoplasty groups</td></tr><tr><th>Patient Group</th><td>152 patients were enrolled in</td></tr><tr><th>Outcome Measure</th><td>Intraocular Pressure</td></tr><tr><th>Result of Intervention</th><td>5.86 mm Hg</td></tr><tr><th>Result of Comparison</th><td>1 year</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 11730649</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/11730649.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>travoprost 0.0015 %</td></tr><tr><th>Comparison Arm</th><td>timolol 0.5 %</td></tr><tr><th>Patient Group</th><td>patients with open-angle glaucoma</td></tr><tr><th>Outcome Measure</th><td>The mean intraocular pressure</td></tr><tr><th>Result of Intervention</th><td>17.9 to 19.2 mm Hg</td></tr><tr><th>Result of Comparison</th><td>-1.3 to -2.8 mm Hg</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 18826749</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/18826749.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>travoprost ( Travatan † )</td></tr><tr><th>Comparison Arm</th><td>a.m.-dosed travoprost and latanoprost</td></tr><tr><th>Patient Group</th><td>Open-angle glaucoma patients naïve to</td></tr><tr><th>Outcome Measure</th><td>Treatment Intraocular Pressure</td></tr><tr><th>Result of Intervention</th><td>treatment groups ( mean</td></tr><tr><th>Result of Comparison</th><td>2.5 mmHg for latanoprost</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 19860553</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/19860553.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>Bimatoprost the fixed combination</td></tr><tr><th>Comparison Arm</th><td>2 medications</td></tr><tr><th>Patient Group</th><td>patients with primary open angle glaucoma</td></tr><tr><th>Outcome Measure</th><td>measured 3 times</td></tr><tr><th>Result of Intervention</th><td>10:00 ( P</td></tr><tr><th>Result of Comparison</th><td>3.28 P</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 20828829</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/20828829.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>the iStent trabecular micro-bypass stent</td></tr><tr><th>Comparison Arm</th><td>combination with cataract surgery</td></tr><tr><th>Patient Group</th><td>240 eyes with mild</td></tr><tr><th>Outcome Measure</th><td>intraocular pressure =24 mmHg</td></tr><tr><th>Result of Intervention</th><td>72 %</td></tr><tr><th>Result of Comparison</th><td>48 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 22344189</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/22344189.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>standard trabeculectomy</td></tr><tr><th>Comparison Arm</th><td>Ex-PRESS implantation</td></tr><tr><th>Patient Group</th><td>adult patients with bilateral Primary Open-Angle Glaucoma</td></tr><tr><th>Outcome Measure</th><td>Intraocular Pressure values</td></tr><tr><th>Result of Intervention</th><td>18 mm Hg</td></tr><tr><th>Result of Comparison</th><td>15.7 ( mm Hg )</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 21792284</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/21792284.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>timolol 0.5 %</td></tr><tr><th>Comparison Arm</th><td>to latanoprost</td></tr><tr><th>Patient Group</th><td>patients with glaucoma</td></tr><tr><th>Outcome Measure</th><td>Intraocular Pressure</td></tr><tr><th>Result of Intervention</th><td>8.3 mmHg</td></tr><tr><th>Result of Comparison</th><td>timolol 23.0 mmHg</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 20584708</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/20584708.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>Balanced Salt Solution Plus</td></tr><tr><th>Comparison Arm</th><td>phacoemulsification 110 patients</td></tr><tr><th>Patient Group</th><td>110 patients undergoing phacoemulsification</td></tr><tr><th>Outcome Measure</th><td>endothelial cell density</td></tr><tr><th>Result of Intervention</th><td>1 , 8 , 15 and 30 days</td></tr><tr><th>Result of Comparison</th><td>4.0 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 10599663</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/10599663.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>a randomized , clinical trial</td></tr><tr><th>Comparison Arm</th><td>the 500-mm2 Baerveldt implant</td></tr><tr><th>Patient Group</th><td>107 patients with uncontrolled intraocular pressure</td></tr><tr><th>Outcome Measure</th><td>Preoperative Intraocular Pressures</td></tr><tr><th>Result of Intervention</th><td>98 %</td></tr><tr><th>Result of Comparison</th><td>79 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 14704542</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/14704542.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>the Baerveldt-350 implant</td></tr><tr><th>Comparison Arm</th><td>the Ahmed valve</td></tr><tr><th>Patient Group</th><td>patients with glaucoma</td></tr><tr><th>Outcome Measure</th><td>an Intraocular Pressure reduction</td></tr><tr><th>Result of Intervention</th><td>12.1 +/- 5.3 mm Hg</td></tr><tr><th>Result of Comparison</th><td>3.2 mm Hg</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 15177955</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/15177955.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>intraoperative Mitomycin C</td></tr><tr><th>Comparison Arm</th><td>Ahmed Glaucoma Valve implantation</td></tr><tr><th>Patient Group</th><td>Sixty patients with refractory glaucoma</td></tr><tr><th>Outcome Measure</th><td>mean Intraocular Pressure</td></tr><tr><th>Result of Intervention</th><td>59 %</td></tr><tr><th>Result of Comparison</th><td>67 %</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 21257146</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/21257146.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>the alpha2-adrenergic agonist brimonidine tartrate</td></tr><tr><th>Comparison Arm</th><td>the beta-adrenergic antagonist timolol maleate</td></tr><tr><th>Patient Group</th><td>Both eyes received twice-daily monotherapy</td></tr><tr><th>Outcome Measure</th><td>glaucoma change probability maps</td></tr><tr><th>Result of Intervention</th><td>9.1 %</td></tr><tr><th>Result of Comparison</th><td>30.0 +/- 2</td></tr></table></div></div><div class="message is-dark"><div class="message-body"><h2 class="title">Paper 20545217</h2><p>Path: /Users/vndluong/FYP_NLP/data/abstracts_structured/20545217.xml</p><table class="table is-bordered is-striped"><tr><th>Intervention Arm</th><td>Tafluprost with Placebo ophthalmic solution</td></tr><tr><th>Comparison Arm</th><td>Placebo Both ophthalmic solutions</td></tr><tr><th>Patient Group</th><td>94 patients enrolled in</td></tr><tr><th>Outcome Measure</th><td>Mean intraocular pressure changes</td></tr><tr><th>Result of Intervention</th><td>-4.0 +/- 1.7 mmHg</td></tr><tr><th>Result of Comparison</th><td>-1.4 +/- 1.8 mmHg</td></tr></table></div></div></div><br/></body></html>